Dogwood Therapeutics, Inc.
$ 2.80
1.82%
24 Feb - close price
- Market Cap 88,227,000 USD
- Current Price $ 2.80
- High / Low $ 2.89 / 2.75
- Stock P/E N/A
- Book Value -14.42
- EPS -25.59
- Next Earning Report 2026-03-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.42 %
- ROE -9.31 %
- 52 Week High 14.69
- 52 Week Low 2.60
About
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company is headquartered in Alpharetta, Georgia.
Analyst Target Price
$19.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-07 | 2025-08-13 | 2025-05-07 | 2025-03-13 | 2024-11-11 | 2024-08-08 | 2024-05-09 | 2024-02-29 | 2023-11-13 | 2023-08-10 | 2023-05-11 | 2023-03-14 |
| Reported EPS | -8.2 | -9.51 | -8.4504 | -6.29 | -2.05 | -0.05 | -0.07 | -0.06 | -0.06 | -0.08 | -0.08 | -0.11 |
| Estimated EPS | -0.05 | -0.05 | -0.765 | -0.0567 | -0.06 | -0.0633 | -0.05 | -0.06 | -0.09 | -0.05 | -0.16 | -0.15 |
| Surprise | -8.15 | -9.46 | -7.6854 | -6.2333 | -1.99 | 0.0133 | -0.02 | 0 | 0.03 | -0.03 | 0.08 | 0.04 |
| Surprise Percentage | -16300% | -18920% | -1004.6275% | -10993.4744% | -3316.6667% | 21.0111% | -40% | 0% | 33.3333% | -60% | 50% | 26.6667% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-30 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -1.22 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: DWTX
2026-02-06 11:59:29
Virios Therapeutics (NASDAQ:VIRI) shares increased 1.7% to $3.08 on Thursday, despite very light trading volume, which was 98% below its daily average. The clinical-stage biopharmaceutical company, focused on fibrotic diseases, has a market cap of $59.31 million and is trading below its 50-day and 200-day moving averages. Its lead drug candidate, VTI-1002, is in trials for hypertrophic scars and keloids, and the stock previously saw a significant jump after a fibromyalgia Phase 3 proposal.
2025-12-22 10:15:00
Dogwood Therapeutics, Inc. today announced positive interim results from its Halneuron® Phase 2b clinical trial for chemotherapy-induced neuropathic pain (CINP). The interim analysis of 97 patients showed that Halneuron® treated patients demonstrated separation from placebo in pain improvement, with top-line results expected in Q3 2026. The study also noted a low dropout rate, suggesting a favorable safety profile for Halneuron®, which has been granted fast track designation by the FDA.
2025-12-05 03:51:57
Virios Therapeutics (NASDAQ:VIRI) saw its share price drop 2.6% during mid-day trading on Tuesday, settling at $6.35 with significantly reduced trading volume compared to its daily average. The development-stage biotech company focuses on treating diseases linked to viral-triggered immune responses, with its lead candidate, IMC-1, targeting fibromyalgia. Despite the recent dip, the stock had previously experienced a 75% increase following a Phase 3 proposal announcement.
2025-11-06 08:45:00
Dogwood Therapeutics reported its third-quarter 2025 financial results, highlighting significant progress in its clinical trials and pipeline development. The company has enrolled 100 patients in its Halneuron® Phase 2b trial and secured an exclusive worldwide license for SP16, a novel treatment for cancer-related pain. Research and development expenses increased to $14.5 million, primarily due to the SP16 licensing agreement and ongoing clinical trial costs, while the net loss attributable to common stockholders was $15.7 million.
2025-10-15 06:44:23
Virios Therapeutics (NASDAQ:VIRI) shares increased by 15.1%, with its stock parameters detailed, including fifty-day and two-hundred-day simple moving averages, market capitalization, P/E ratio, and beta. The article also provides a company profile, highlighting Virios Therapeutics as a development-stage biotechnology company focused on antiviral therapies, with IMC-1 for fibromyalgia as its lead candidate.
2025-08-07 13:08:00
Dogwood Therapeutics announced the enrollment of the first 50 patients in its ongoing Halneuron® Phase 2b trial for Chemotherapy-Induced Neuropathic Pain (CINP). The company expects interim data readout for approximately 100 patients in Q4 2025 and plans to release full results in mid-2026. The trial is evaluating Halneuron® as a non-opioid NaV1.7 inhibitor, which has received Fast Track designation from the FDA for CINP treatment.
